BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
Helix clinical data span fifteen trials involving nearly five hundred patients, while marketing clearance remains pending.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (NASDAQ: BCDA) announced FDA acceptance of its revised De Novo pre-submission package seeking marketing clearance for the Helix catheter. Helix is intended to deliver therapeutic and diagnostic agents. At a May 2026 meeting, FDA agreed there were two clearance pathways and raised no concerns about safety data, performance or compatibility with general classes of agents. FDA accepted the meeting minutes in August; BioCardia revised and resubmitted the package in September.
BioCardia expects written FDA feedback and a meeting this quarter to discuss approval through the De Novo pathway. Clinical data cover fifteen trials involving nearly five hundred patients. Acceptance of the pre-submission is not marketing clearance. The company sees potential for clearance to expand partnerships with developers of investigational therapies requiring targeted delivery to the heart.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA accepted the revised De Novo pre-submission for Helix marketing clearance.
- Minor pointFDA raised no concerns about safety data, performance or compatibility with general classes of agents.
- Minor pointHelix clinical data span fifteen trials involving nearly five hundred patients.
- Minor point. Forward-looking: it has not happened yet and may not happen.BioCardia expects FDA written feedback and a meeting this quarter on the De Novo pathway.
- Minor point. Forward-looking: it has not happened yet and may not happen.BioCardia sees potential partnership expansion with investigational therapy developers if Helix receives marketing clearance.
Negative
- Moderate pointHelix marketing clearance remains pending; acceptance covers the pre-submission package.
Details
Market Reaction – BCDA
On Oct 19, the day this news came out, the latest delayed price for BCDA is 0.57% below the previous close. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $0.91. Relative volume is exceptionally heavy at 9.9x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Clinical trials
- 15 clinical trials
- Helix clinical data and safety profile
- Patients
- Nearly 500 patients
- Helix clinical data and safety profile
Historical Context
-
Filed revised Helix De Novo pre-submission incorporating FDA advice after accepted meeting minutes.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
de novo regulatory
cdrh regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter (“Helix”) intended for therapeutic and diagnostic agent delivery.
In May 2026, the Company and FDA met and reviewed our initial De Novo pre-submission package. FDA agreed that there are two pathways for Helix marketing clearance and raised no concerns regarding the product’s safety data, performance, or compatibility with general classes of agents. In August 2026, FDA confirmed and accepted the meeting minutes. In September 2026, the De Novo pre-submission was revised, incorporating the advice from FDA CDRH as detailed in the meeting minutes, re-submitted and has now been accepted by FDA. BioCardia expects FDA substantive review with written feedback, followed by a meeting with BioCardia to discuss approval via the De Novo pathway, this quarter.
The extensive clinical data and safety profile from fifteen clinical trials including nearly five hundred patients presents an opportunity for FDA to ensure that follow-on catheters demonstrate a similar level of safety and clinical experience to obtain clearance.
Marketing clearance of Helix by FDA has the potential to expand BioCardia’s opportunities to partner with developers of investigational cells, genes, and protein therapeutics requiring targeted delivery to the heart.
About the Helix Transendocardial Delivery Catheter
The Helix transendocardial delivery catheter is an enabling platform for minimally invasive targeted delivery of therapeutic and diagnostic agents to the heart intramyocardially. It enables agents to be delivered precisely within the heart with superior retention over other therapeutic delivery modalities, and to many regions of the heart that other delivery methods cannot reach. The Helix includes a specialized small distal helical needle which engages the heart tissue from within the chamber of the heart and provides stability within the dynamic beating heart to safely enable agent delivery.
About BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, the ability to enter into licensing and partnering arrangements, and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Did FDA approve BioCardia's Helix catheter for marketing?
FDA accepted Helix's revised De Novo pre-submission package, not marketing clearance. The package seeks clearance for delivery of therapeutic and diagnostic agents.
When does BioCardia expect FDA feedback on the Helix catheter?
BioCardia expects substantive FDA review with written feedback followed by a meeting this quarter. The meeting would discuss approval through the De Novo pathway.